Bocchia and colleagues reported that CD26+ LSCs persist in the majority of CML patients who are in molecular response while receiving TKI treatment, and even after TKI discontinuation, without any correlation between BCR::ABL1 levels and the number of residual LSCs [46]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.